Equillium announces the appointment of katherine xu to the board of directors

La jolla, calif., feb. 09, 2021 (globe newswire) -- equillium, inc. (nasdaq: eq) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that y. katherine xu, ph.d., partner at decheng capital, has been appointed to equillium's board of directors, effective thursday, february 4, 2021.
EQ Ratings Summary
EQ Quant Ranking